NCT05522387 2026-02-27An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseInmune Bio, Inc.Phase 2 Terminated11 enrolled
NCT06723015 2025-11-18Tau PET Outcomes With Anti-amyloid ImmunotherapiesMayo ClinicPhase 2 Enrolling by invitation135 enrolled
NCT05321498 2023-09-28Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of InflammationInmune Bio, Inc.Phase 2 Withdrawn